Johnson & Johnson Announces New Two-year Results From Its Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE In Adults With Moderate-To-Severe Plaque Psoriasis; Data Demonstrated Consistently High Levels Of Skin Clearance And Patient-Reported Symptom... — Ultime notizie